Remus Pharmaceuticals approved its audited H1/FY2026 results with an unmodified opinion, proposed a final dividend of ₹0.50 per share, and approved appointments of a Secretarial Auditor and an Internal Auditor.
AI Assistant
Remus Pharmaceuticals Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.